Impact of Adduct Determination on the Assessment of Cancer Susceptibility

  • H. Bartsch
  • M. Rojas
  • K. Alexandrov
  • A. Risch
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 154)

Abstract

The characterization of genetic determinants for cancer susceptibility is important for understanding disease pathogenesis and for preventive measures. There is growing evidence that a group of predisposing polymorphic genes exists, such as those involved in carcinogen metabolism and repair, which may increase cancer in certain environmentally exposed subjects, even those exposed only to low levels of carcinogens. In developing preventive strategies, it is therefore necessary to identify these vulnerable members in our society, particularly those suffering from an unfortunate combination of high carcinogen exposure, cancer-predisposing genes and lack of protective (dietary) factors. Thus, molecular epidemiology faces the difficult task of analyzing carcinogen-exposed individuals for a combination of genotypes associated with cancer susceptibility. Once identified, combinations of cancer-predisposing genes can then be used as intermediate risk markers rather than taking cancer as an endpoint. In case-control studies, simultaneous measurements were carried out in each subject to determine exposure/early effect markers, e.g. polycyclic aromatic hydrocarbons (PAH)-DNA adducts, and susceptibility markers, e.g. genetic polymorphism, in drug-metabolizing enzymes related to cytochrome P450 1A1 (CYP1A1) and glutathione S-transferase (GSTM1) genes. The genotype dependence of human lung (+)-antibenzo[a]pyrene diol-epoxide (BPDE)-DNA adducts in lung cancer patients was examined. BPDE-DNA adduct levels in bronchial tissue of smokers with high pulmonary CYP1A1 inducibility (by immunohistochemistry) and GSTM1 inactive were ~100-fold higher than in subjects with an active GSTM1 at similar smoking dose. Further genetic analyses confirmed that the combination of CYP1A1 homozygous mutants and GSTM1 inactive leads to high levels of BPDE-DNA adducts in human lung of smokers and white blood cells of PAH-exposed coke oven workers. Thus, BPDE-DNA adduct levels resulting from the “at risk” genotype combinations may serve as markers to identify high-risk subjects among smokers and individuals occupationally and/or environmentally exposed to PAH.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alexandrie AK, Sundberg MI, Seidegard J, Tornling G, Ranung A (1994) Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis 15: 1785–1790PubMedCrossRefGoogle Scholar
  2. Alexandrov K, Rojas M, Geneste O, Castegnaro M, Camus AM, Petruzzelli S, Giuntini C, Bartsch H (1992) An improved fluorometric assay for dosimetry of benzo[a]pyrene diolepoxide-DNA adducts in smoker’s lung: comparison with total bulky adducts and aryl hydrocarbon hydroxylase activity. Cancer Res 52: 6248–6253PubMedGoogle Scholar
  3. Bartsch H (1996) DNA adducts in human carcinogenesis: etiological relevance and structureactivity relationship. Mutat Res 40: 67–79Google Scholar
  4. Bartsch H, Hietanen E (1996) The role of individual susceptibility in cancer burden related to environmental exposure. Environ Health Perspect 104 (Suppl 3): 569–577PubMedCrossRefGoogle Scholar
  5. Bartsch H, Hietanen E, Petruzzelli S, Giuntini C, Saracci R, Mussi A, Angeletti CA (1990) Possible prognostic value of pulmonary Ah-locus-linked enzymes in patients with tobacco-related lung cancer. Int J Cancer 46: 185–188PubMedCrossRefGoogle Scholar
  6. Bartsch H, Rojas M, Alexandrov K, Camus A-M, Castegnaro M, Malaveille C, Anttila S, Hirvonen K, Husgafvel-Pursiainen K, Hietanen E, Vainio H (1995) Metabolic polymorphism effecting DNA binding and excretion of carcinogens in humans. Pharmacogenetics 5: S84 - S90PubMedCrossRefGoogle Scholar
  7. Brockmöller J, Kerb R, Drakoulis N, Nitz M, Roots I (1993) Genotype and phenotype of glutathione S-transferase class isoenzymes in lung cancer patients and controls. Cancer Res 53: 1004–1011PubMedGoogle Scholar
  8. Caporaso N, Goldstein A (1995) Cancer genes: single and susceptibility: exposing the difference. Pharmacogenetics 5: 59–63PubMedCrossRefGoogle Scholar
  9. Cascorbi I, Brockmöller J, Roots I (1996) A C4887A polymorphism in exon 7 of human CYPIA1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 56: 4965–4969PubMedGoogle Scholar
  10. Denissenko MF, Pao A, Tang MS, Pfeifer GP (1996) Preferential formation of ben- zo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 274: 430–432PubMedCrossRefGoogle Scholar
  11. Goto M, Yoneda S, Yamamoto M, Kawajiri K (1996) Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res 6: 3725–3730Google Scholar
  12. Hayashi SI, Watanabe J, Kawajiri K (1992) High susceptibility to lung cancer analyzed in terms of combined genotypes of P4501A1 and Mu-class glutathione S-transferase genes. Jpn J Cancer Res 83: 866–870PubMedCrossRefGoogle Scholar
  13. Hsu TC (1987) Genetic predisposition to cancer with special reference to mutagen sensitivity. In vitro Cellular and Developmental Biology 23: 591–603PubMedCrossRefGoogle Scholar
  14. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J (1990) Identification of genetically high risk individuals to lung cancer by DNA polymorphism of the cytochrome P4501A1 gene. FEBS Lett 263: 131–133PubMedCrossRefGoogle Scholar
  15. Kihara M, Kihara M, Noda K (1995) Risk of smoking for squamous and small cell carcinomas of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorph-isms in a Japanese population. Carcinogenesis 16: 2331–2336PubMedCrossRefGoogle Scholar
  16. McWilliams JE, Sanderson BJS, Harris EL, Richert-Boe KE, Henner WD (1995) Glutathione S-transferase M1 (GSTM1) deficiency and lung cancer risk. Cancer Epidemiol Biomarkers Prey 4: 589–594Google Scholar
  17. Nakachi K, Imai K, Hayashi S-I, Watanabe J, Kawajiri K (1991) Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res 51: 5177–5180PubMedGoogle Scholar
  18. Nakachi K, Imai K, Hayashi S-I, Kawajiri K (1993) Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 53: 2994–2999PubMedGoogle Scholar
  19. Nakajima T, Elovaara E, Anttila S, Hirvonen A, Camus A-M, Hayes JD, Ketterer B, Vainio H (1995) Expression and polymorphism of glutathione S-transferase in human lungs: risk factors in smoking-related lung cancer. Carcinogenesis 16: 707–711PubMedCrossRefGoogle Scholar
  20. Rojas M, Alexandrov K, van Schooten F-J, Hillebrand M, Kriek E, Bartsch H (1994) Validation of a new fluorometric assay for benzo[a]pyrene diolepoxide-DNA adducts in human white blood cells: comparison with 32P-postlabeling and ELISA. Carcinogenesis 15: 557–560PubMedCrossRefGoogle Scholar
  21. Rojas M, Alexandrov K, Auburtin G, Wastiaux-Denamur A, Mayer L, Mahieu B, Sebastien P, Bartsch H (1995) Anti-benzo[a]pyrene diolepoxide-DNA adduct levels in peripheral mononuclear cells from coke oven workers and the enhancing effect of smoking. Carcinogenesis 6: 1373–1376CrossRefGoogle Scholar
  22. Rojas M, Alexandrov K, Cascorbi I, Brockmöller J, Likhachev A, Pozharisski K, Bouvier G, Auburtin G, Mayer L, Koop-Schneider A, Roots I, Bartsch H (1998) High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from subjects with combined CYP1A1 MspI/MspI-GSTM1*0/*0 genotypes. Pharmacogenetics 8: 109–118PubMedCrossRefGoogle Scholar
  23. Ryberg D, Kure E, Lystad S, Skaug V, Stangeland L, Mercy I, Bi rresen A-L, Haugen A (1994) p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer. Cancer Res 54: 1551–1555Google Scholar
  24. Tang D, Santella RM, Blackwood AM, Young T-L, Mayer J, Jaretzki A, Grantham S, Tsai W-Y, Perera FP (1995) A molecular epidemiological case-control study of lung cancer. Cancer Epidemiol Biomarkers Prey 4: 341–346Google Scholar
  25. Van Schooten FJ, Jongeneelen FJ, Hillebrand MJX, van Leeuwen FE, de Loof AJA, Dijkmans APG, van Rooij JGM, den Engelse L, Kriek E (1995) Polycyclic aromatic hydrocarbon-DNA adducts in white blood cell DNA and 1-hydroxypyrene in the urine from aluminum workers: relation with job category and synergistic effect of smoking. Cancer Epidemiol Biomarkers Prey 4: 69–77Google Scholar
  26. Vaury C, Laine R, Noguiez P, de Coppet P, Jaulin C, Praz F, Pompon D, Amor-Guéret M (1995) Human glutathione S-transferase M1 null genotype is associated with a high inducibility of cytochrome P450 1A1 gene transcription. Cancer Res 55: 5520–5523PubMedGoogle Scholar
  27. Vineis P (1997) Molecular epidemiology: low-dose carcinogens and genetic susceptibility. Int J Cancer 71: 1–3PubMedCrossRefGoogle Scholar
  28. Vineis P, Bartsch H, Caporaso N, Harrington AM, Kadlubar FF, Landi MT, Malaveille C, Shields PG, Skipper P, Talaska G, Tannenbaum SR (1994) Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 369: 154–156PubMedCrossRefGoogle Scholar
  29. Wiencke JK, Kelsey KT, Varkonyi A, Semey K, Wain JC, Mark E, Christiani DC (1995) Correlation of DNA adducts in blood mononuclear cells with tobacco carcinogen-induced damage in human lung. Cancer Res 55: 4910–4914PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1998

Authors and Affiliations

  • H. Bartsch
    • 1
  • M. Rojas
    • 1
  • K. Alexandrov
    • 1
  • A. Risch
    • 1
  1. 1.Division of Toxicology and Cancer Risk FactorsGerman Cancer Research Center (DKFZ)HeidelbergGermany

Personalised recommendations